Rx · Prescription onlyInjected under the skin
CJC-1295 / Ipamorelin
Your own growth hormone.
Your plan
$229/mo, $1,374 billed once for 6 months/mo
$1,374 billed once for 6 months · unused months refunded on a medical stop
No membership fee · this is the full price · free shipping · avg 4-week supply
- Medication, clinician care and dose adjustments, all in one price.
- ~28-day supply. Your clinician sets your exact dose, so yours may vary; your refill arrives as you finish the last one.
A licensed clinician on our care team reviews every request and prescribes only when it's clinically appropriate.
FDA status: Compounded medication, not FDA-approved.
What it's for
Who it's for
Adults who want the best-known growth hormone peptide pair for sleep, recovery and body composition.
How it's different
CJC-1295 lengthens the growth hormone pulse and ipamorelin triggers it; together they aim for a stronger, cleaner pulse.
How it works
CJC-1295 is a modified version of growth hormone-releasing hormone (GHRH) that keeps the signal to your pituitary active for longer. Ipamorelin acts on a second receptor (the ghrelin receptor) to release growth hormone selectively, with little effect on cortisol or prolactin. Together they raise the size of your own natural growth-hormone pulses rather than replacing them.
How to use it and what arrives
1 vial · lasts 4 weeks
1.2 mg / 2 mg/mL · 5 mL vial
- How
- Injected under the skin
- How often
- 5 days a week
- When
- At bedtime
Good to know
Inject at bedtime on an empty stomach. Food, especially sugar, blunts the pulse.
What the research shows
Two growth-hormone-releasing peptides. CJC-1295 has a short human Phase 1 study; ipamorelin has been studied mainly in animals.
Healthy adults
2 to 10-fold GH rise
In two randomized, placebo-controlled trials in healthy adults aged 21 to 61 (28 and 49 days), growth hormone rose 2- to 10-fold for six days or more after subcutaneous CJC-1295, and IGF-I rose 1.5- to 3-fold for 9 to 11 days. No serious adverse reactions were reported.
Teichman et al., J Clin Endocrinol Metab 2006Ipamorelin
animal data
Raun et al. (1998) describe ipamorelin as a selective growth hormone releaser. In animal studies it released growth hormone without raising ACTH or cortisol. It is an animal study, not a human trial.
Raun et al., Eur J Endocrinol 1998Efficacy
no efficacy trials
We found no published Phase 2 or Phase 3 trial showing a clinical benefit of the combination in any condition. The 2006 study measured hormone levels, not outcomes.
Teichman et al., J Clin Endocrinol Metab 2006
The 2006 trial studied CJC-1295, a long-acting form, in healthy people over several weeks. Hormone responses are averages from research subjects, not predictions for anyone. Ipamorelin has no published controlled human trial in this review. Compounded versions were not studied.
What this does not say
- No human trial measured body composition, recovery, sleep or any health outcome for this combination.
- The studied adults were healthy; the effects of long-term use in people with other conditions are not known.
- Growth hormone raises IGF-I, and the long-term effects of sustained elevation are not established.
Sources
- Ipamorelin, the first selective growth hormone secretagogue: release of growth hormone without cortisol or prolactin. Eur J Endocrinol, 1998
- Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab, 2006
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging, 2006
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab, 2015
- Metabolic effects of a growth hormone-releasing factor (tesamorelin): randomized trial showing reduced visceral fat. N Engl J Med, 2007
- Effects of tesamorelin on non-alcoholic fatty liver disease: randomised, double-blind, multicentre trial. Lancet HIV, 2019
Safety
FDA status: Compounded medication, not FDA-approved.
Side effects and precautions
- Growth hormone-releasing peptides are generally well tolerated.
- Common, mild effects include redness or a small bump at the injection site, headache, flushing, water retention, tingling in the hands or joint aches in the first weeks, and vivid dreams as sleep deepens.
- MOTS-c may change blood sugar responses: tell your clinician if you take diabetes medication.
Get care right away
- Stop and seek care for hives, swelling of the face or lips or trouble breathing.
When it isn't prescribed
- They are not prescribed with an active cancer, a cancer under evaluation, uncontrolled diabetes, or during pregnancy or breastfeeding, and they are used with care in people with a history of pituitary disease.
Tell your clinician about every medication you take.
Questions
How is this different from sermorelin?
Sermorelin is a shorter-acting GHRH analog. CJC-1295 keeps the GHRH signal active longer, and ipamorelin adds a second, selective pathway. Many people describe a stronger effect on sleep and recovery; your clinician decides which fits your goals and history.
How do I take it?
A small subcutaneous injection with an insulin-style needle, most often at night before bed, on an empty stomach. Your clinician sets the dose and schedule; MOTS-c is often a few times a week rather than nightly. The kit includes everything.
Is this the same as HGH?
No. These peptides prompt your pituitary to release your own growth hormone in its natural pulses, so the body's feedback loops stay in control. Synthetic HGH bypasses those loops. That difference is why the side-effect profile is milder.
What are the side effects?
Mild for most people: injection-site redness, headache, flushing, water retention, tingling or joint aches in the first weeks, and vivid dreams. Not prescribed with an active or suspected cancer or in pregnancy. Read the safety information above.
Ready to start with CJC-1295 / Ipamorelin?
$229/mo · $1,374 billed once for 6 months
- Free shipping on every order
- No membership fee
- Same price at every dose
- HSA and FSA accepted
